Triple therapy aims to wipe out colorectal cancer before surgery

NCT ID NCT07691632

Not yet recruiting Disease control Sponsor: Tianjin Medical University Cancer Institute and Hospital Source: ClinicalTrials.gov ↗

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether giving a combination of an immunotherapy drug (serplulimab), an epigenetic drug (decitabine), and chemotherapy (CAPOX) before surgery can improve outcomes for people with locally advanced colorectal cancer. The study enrolls 35 adults with previously untreated stage cT3/cT4N+M0 colorectal adenocarcinoma. Participants receive four cycles of the drug combination, then undergo surgery. The main goal is to see how many patients have no cancer cells left in their surgical specimen (pathological complete response).

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Serplulimab, Decitabine, Oxaliplatin, Capecitabine
What this could lead to: If successful, this combination could become a new pre-surgery treatment option that increases the chance of eliminating all cancer cells before surgery for patients with locally advanced colorectal cancer.
What could go wrong: This is a small, early-phase study (35 people) with no control group, so results may not apply broadly. The drug combination may cause significant side effects, and the added benefit over standard chemotherapy alone is uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal adenocarcinoma colorectal cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL ADENOCARCINOMA LOCALLY ADVANCED COLORECTAL CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Tianjin Medical University Cancer Institute & Hospital

Tianjin, Tianjin Municipality, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.